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Abstract
Ipilimumab, an antibody that enhances T-cell activation, may augment immuno-
genicity of tumor cells that are injured by radiation therapy. We hypothesized that
patients with melanoma brain metastasis treated with both ipilimumab and radio-
therapy would have improved overall survival, and that the sequence of treat-
ments may affect disease control in the brain. We analyzed the clinical and
radiographic records of melanoma patients with brain metastases who were trea-
ted with whole brain radiation therapy or stereotactic radiosurgery between 2005
and 2012. The hazard ratios for survival were estimated to assess outcomes as a
function of ipilimumab use and radiation type. Seventy patients were identified,
33 of whom received ipilimumab and 37 who did not. The patients who received
ipilimumab had a censored median survival of 18.3 months (95% confidence
interval 8.1–25.5), compared with 5.3 months (95% confidence interval 4.0–7.6)
for patients who did not receive ipilimumab. Ipilimumab and stereotactic radio-
surgery were each significant predictors of improved overall survival (hazard
ratio = 0.43 and 0.45, with P = 0.005 and 0.008, respectively). Four of 10 evalu-
able patients (40.0%) who received ipilimumab prior to radiotherapy demon-
strated a partial response to radiotherapy, compared with two of 22 evaluable
patients (9.1%) who did not receive ipilimumab. Ipilimumab is associated with a
significantly reduced risk of death in patients with melanoma brain metastases
who underwent radiotherapy, and this finding supports the need for multimodali-
ty therapy to optimize patient outcomes. Prospective studies are needed and are
underway.
Introduction
Brain metastases from melanoma are prevalent and clini-
cally devastating. Most patients who develop melanoma
brain metastases (MBM) die of neurologic sequelae [1].
Local therapy, such as surgery or radiation, has tradition-
ally been the mainstay of treatment. The use of whole
brain radiation therapy (WBRT) may impact on neuro-
logic deaths of patients with MBM as compared to best
supportive care, but the overall survival (OS) following
WBRT remains dismal at 3–4 months [2]. Stereotactic
radiosurgery (SRS) is often used for limited numbers of
small metastases, but the median survival following SRS is
only 5–6 months [3, 4].
Ipilimumab, an antibody that blocks the cytotoxic
T-lymphocyte antigen-4 (CTLA-4) immune checkpoint,
was approved by the United States Food and Drug
Administration (FDA) based on an OS advantage in
patients with metastatic melanoma [5]. Patients with
active, untreated brain metastases were excluded from the
phase III trials [5, 6]. In a dedicated phase II study of
ipilimumab in patients with brain metastases, Margolin
et al. [7] reported that ipilimumab had activity in the
brain which was similar to systemic activity, with a
response rate of 16% in neurologically asymptomatic sub-
jects. Median survival was 3.7 months in patients who
had neurologic symptoms at enrollment and 7.0 months
in patients who did not. More than 40% of patients had
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previously received radiation to the brain prior to enroll-
ment. In a retrospective study of 77 patients with MBM
who underwent SRS, ipilimumab therapy was associated
with a 16-month improvement in median survival over
those that did not receive ipilimumab [8]. In a similar
retrospective series of 58 patients, a 10% improvement in
6-month OS was seen, although it was not statistically
significant [9]. Importantly, responses in the brain, as in
extracranial disease, may be durable [10].
No data are currently available from trials of concur-
rent ipilimumab and radiation therapy (RT), although
these are actively accruing. To better understand the effect
of ipilimumab on the outcomes of patients with MBM
and potentially guide the design of future clinical trials,
we reviewed our experience with patients treated with
WBRT and SRS who did and did not receive ipilimumab.
Given the existing research in this area, we hypothesized
that patients with melanoma brain metastasis treated with
both ipilimumab and radiotherapy would have improved
OS, and that the sequence of treatments may affect dis-
ease control in the brain.
Methods
The clinical and radiographic records of patients with
MBM at the University of Michigan between 2005 and
2012 were reviewed. Within that population, those
patients who underwent RT for brain metastases and
received one or more doses of ipilimumab (either before
or after RT) were identified and included in the analy-
sis. Ipilimumab was given intravenously at a dose of
3 mg/kg every 3 weeks for a planned four doses. A rein-
duction course was given for some patients who experi-
enced disease control with the initial course. Whole
brain radiotherapy and SRS were both included to
explore the effects of radiation delivery, schedule, and
dose intensity.
As a comparison group for the patients who received
ipilimumab and WBRT, 21 patients with melanoma were
identified from participation in a phase I clinical trial of
WBRT with concurrent bortezomib as a potential radio-
sensitizer in 2007–2009 [11]. None of these participants
received ipilimumab at any point during their course of
treatment. As a comparison group for the patients who
received ipilimumab and SRS, we identified serial cases
from 2005 to 2011 who underwent SRS prior to the FDA
approval of ipilimumab. This study was approved by the
University of Michigan Institutional Review Board (IRB
protocol #67184).
Outcomes of interest were OS, time to progression in
the brain (TTPbr), and proportion of patients with a
response to RT. Data on the clinical courses of these
patients were extracted from their medical records,
including brain imaging, subsequent treatments, survival,
and serum lactate dehydrogenase (LDH) level [12, 13].
Intratumoral hemorrhage [14] and radiation necrosis
[15] were defined as present if noted explicitly as new or
worsening signs of bleeding. We calculated prognostic
scores by two commonly used methods: the recursive
partitioning analysis (RPA) score [4] and the diagnosis-
specific graded prognostic assessment (DS-GPA) for
melanoma [16]. Both of these scales incorporate perfor-
mance status and number of brain metastases, which are
recognized as important prognostic variables. The distri-
butions of baseline variables for patients either receiving
or not receiving ipilimumab were compared using chi-
square tests for categorical variables and two-sample
t-tests for continuous variables. Survival was measured
from the date of the first RT to the brain, and the events
of interest were progression of brain metastases and
death. Patients who had objective evidence of progression
of brain metastases prior to death and who displayed
altered mental status or failure to thrive leading up to
the time of death were categorized as dying of brain
metastases. Survival data were considered right censored
at the date of last follow-up (2/15/13) if the events of
interest had not been observed as of that date. Patients
were evaluable for response if lesions were 5 mm or lar-
ger in longest diameter on baseline imaging and repeat
imaging was performed 4–16 weeks after RT, prior to the
patient receiving additional therapy. The proportion of
patients with complete response (CR) or partial response
(PR) to RT and TTPbr were classified using both response
evaluation criteria in solid tumors (RECIST) [17] and
immune-related response criteria (irRC) [18] as per Mar-
golin et al. [7].
Descriptive statistics for the survival times and 95%
confidence intervals for the median survival times were
used to summarize the courses of our subjects. The
nonparametric K-sample test was used to compare the
equality of median survival times. Fisher’s exact test
was used to compare the proportions of responses
between the ipilimumab and comparison groups. A Cox
regression model was used to estimate the hazard ratios
(HR) associated with the ipilimumab and SRS treat-
ments, as both ipilimumab and fewer brain metastases
have been associated with improved survival [4–6, 16].
In the Cox model, we also tested the significance of an
interaction between the ipilimumab and SRS treatment
indicators, and performed a post hoc power calculation
for the interaction term (given our small sample sizes).
Available commands in the Stata 12.1 software (exact,
median, stci, stcox, and sts graph) were used for all
analyses, and the R function powerEpiInt() in the R
package powerSurvEpi was used for the post hoc power
calculation.
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Results
Thirty-three patients with MBM received ipilimumab (12
before RT and 21 after RT). Among the patients who
received ipilimumab, 16 underwent WBRT and 17 under-
went SRS. The median number of doses of ipilimumab
received was 4 (range, 1–8). Among the 37 patients in the
comparison groups, 21 underwent WBRT (in a phase I
trial of concurrent bortezomib) [11] and 16 underwent
SRS. The average interval between the first dose of
ipilimumab and RT was 23 weeks. There were no signifi-
cant differences between the ipilimumab groups and the
comparison groups with respect to age, sex, type of mela-
noma, number of brain metastases, prior craniotomy sta-
tus, performance status, and prognostic indicators
(Table 1). The frequency of patients who received any
prior and subsequent systemic therapy was similar; how-
ever, 13 patients (39.4%) in the ipilimumab groups
received BRAF inhibitor therapy, which was significantly
more than in the comparison groups. Those patients
received either vemurafenib or dabrafenib, which was
available at the University of Michigan as part of a clini-
cal trial. BRAF mutational status was known for all of
patients in the ipilimumab groups, but only 11% in the
comparison groups due to the year of treatment. Patients
in the ipilimumab groups also received additional RT to
the brain more frequently (54.6% vs. 8.1%).
Thirty-seven patients received WBRT and 33 patients
received SRS for the treatment of MBM. Patients who
received WBRT were treated with 30–37.5 Gy in 10–13
fractions. The number of lesions present at the time of
WBRT ranged from 1 to 62. Patients who were treated with
SRS received 14–24 Gy in 1–5 fractions. The SRS treatment
volume size ranged from 0.19 to 17.2 cc. The number of
lesions present at the time of SRS ranged from 1 to 14.
Of the 70 patients, 55 died and the surviving 15 had at
least 10 months of follow-up time. Patients who received
ipilimumab had a median survival of 18.3 months, as
compared with 5.3 months for those who did not receive
ipilimumab (Table 2). In the Cox regression analysis,
treatment with ipilimumab was found to be a statistically
significant predictor of improved survival (HR = 0.43,
P = 0.005; Fig. 1). Regarding the sequence of the thera-
pies, the censored OS was 8.1 months for the patients
who received ipilimumab before RT, versus 18.4 months
for the patients who received ipilimumab after RT. Treat-
ment with SRS as compared to WBRT was also a statisti-
cally significant predictor of improved survival
(HR = 0.45, P = 0.008). Patients in the SRS groups had
fewer brain metastases as compared to patients in the
WBRT groups, with a median of 1 versus 6 brain metas-
tases. Most patients died of their brain metastases (70%
in the comparison groups and 81% in the ipilimumab
Table 1. Characteristics of the study population.
No ipilimumab
(n = 37)
Ipilimumab
(n = 33) P-value
Type of RT
WBRT 21 (56.8%) 16 (48.5%) 0.49
SRS 16 (43.2%) 17 (51.5%)
Years
treated
2005–2011 2009–2012 Not
applicable
Mean age (years) 57.7 56.6 0.76
Sex
Female 17 (45.9%) 13 (39.4%) 0.58
Male 20 (54.1%) 20 (60.6%)
Type of melanoma
Cutaneous 31 (83.8%) 32 (97.0%) 0.13
Mucosal 2 (5.4%) 1 (3.0%)
Unknown
primary
4 (10.8%) 0 (0%)
Number of brain
metastases
>3 16 (43.2%) 18 (54.6%) 0.39
2 or 3 9 (24.3%) 4 (12.1%)
1 12 (32.4%) 11 (33.3%)
Craniotomy prior
to RT
Yes 7 (18.9%) 6 (18.2%) 0.94
No 30 (81.1%) 27 (81.8%)
ECOG PS
0 16 (45.7%) 15 (53.6%) 0.15
1 12 (34.3%) 12 (42.9%)
2–31 7 (20.0%) 1 (3.6%)
Neurologic symptoms
Asymptomatic 20 (54.0%) 25 (75.8%) 0.06
Symptomatic 17 (46.0%) 8 (24.2%)
RPA
Class I 1 (2.7%) 0 (0%) 0.34
Class II 36 (97.3%) 33 (100%)
DS-GPA
0–1 8 (24.2%) 7 (25.0%) 0.99
2 12 (36.4%) 11 (39.3%)
3 9 (27.3%) 7 (25.0%)
4 4 (12.1%) 3 (10.7%)
Serum LDH level
Normal 20 (62.5%) 18 (64.3%) 0.89
Elevated 12 (37.5%) 10 (35.7%)
BRAF status
Mutated 3 (25.0%) 17 (51.5%) 0.37
Wild type 1 (75.0%) 16 (48.5%)
Prior systemic
therapy2
Yes 19 (51.4%) 14 (42.4%) 0.46
No 18 (48.6%) 19 (57.6%)
Subsequent systemic
therapy3
Yes 22 (62.9%) 18 (54.5%) 0.49
No 13 (37.1%) 15 (45.5%)
Subsequent brain RT
Yes 3 (8.1%) 18 (54.6%) <0.001
No 33 (89.2%) 15 (45.5%)
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groups). Median TTPbr using irRC was ~3 months in all
treatment groups (Table 2).
Exploratory subgroup analyses by type of RT revealed
an apparent initial decrement in the survival of the
WBRT patients who received ipilimumab until
~6 months, at which point the survival curves cross
(Fig. 2A). Treatment with ipilimumab was not signifi-
cantly associated with survival in the WBRT subset
(HR = 0.56, P = 0.15). The median survival of WBRT
patients who did or did not receive ipilimumab was 3.1
versus 5.3 months, respectively (P = 0.60, not significant;
Table 2). Among patients who underwent SRS, treatment
with ipilimumab was significantly associated with
improved survival (HR = 0.31, P = 0.009; Fig. 2B). These
patients had a censored median survival of 19.9 months,
whereas the censored median survival in patients who
underwent SRS but did not receive ipilimumab was
4.0 months (Table 2), and this difference was statistically
significant (P = 0.009). Among the SRS subset, we found
no significant differences in the patient characteristics
except for Eastern Cooperative Oncology Group (ECOG)
performance status (P = 0.043), neurologic symptoms
(P = 0.013), subsequent brain RT (P = 0.016), and BRAF
inhibitor treatment (P = 0.049), all favoring the ipi-
limumab group. To explore the possibility that the combi-
nation of treatment with ipilimumab and SRS would
improve the outcomes of interest, we tested the significance
of the interaction between these two treatment indicators
in the Cox regression model. Although the estimated
hazard ratio for treatment with ipilimumab was 0.32 in the
SRS treatment group as compared to 0.57 in the group that
did not receive SRS, the interaction was not statistically
significant (P = 0.31); however, there was insufficient
power (19%) to detect a significant interaction in a post
hoc power calculation.
Due to the fact that subsequent therapies may have
impacted the OS, the effect of ipilimumab on response
rate to brain RT and TTPbr was also analyzed. Forty-four
patients were evaluable for response using irRC. Response
rate and TTPbr using RECIST was similar, except for
three patients (two in the ipilimumab groups and one in
the comparison) who were classified as stable disease
rather than progressive disease (not shown). There were
no CRs (Table 3). The responses of patients who received
ipilimumab versus the comparison groups were not sig-
nificantly different using Fisher’s exact test (P = 0.238;
Table 1. Continued.
No ipilimumab
(n = 37)
Ipilimumab
(n = 33) P-value
BRAF inhibitor ever
Yes 1 (3.1%) 13 (39.4%) <0.001
No 31 (96.9%) 20 (60.6%)
RT, radiation therapy; WBRT, whole brain radiation therapy; SRS,
stereotactic radiosurgery; PS, performance status; RPA, recursive parti-
tioning analysis; DS-GPA, diagnosis-specific graded prognostic assess-
ment; LDH, lactate dehydrogenase.
1One patient in the ipilimumab group had an ECOG PS of 3 and the
remainder had PS of 2.
2Not including ipilimumab. Prior therapies included interferon, inter-
leukin-2, tumor-infiltrating lymphocytes, cytotoxic chemotherapy, and
BRAF inhibitors (four patients in the ipilimumab group).
3Not including ipilimumab. Subsequent therapies included cytotoxic
chemotherapy and BRAF inhibitors (nine patients in the ipilimumab
group).
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Figure 1. Censored overall survival of all patients by ipilimumab
treatment. Treatment with ipilimumab was significantly associated
with improved survival (HR = 0.43, P = 0.005). HR, hazard ratio.
Table 2. Censored median TTPbr and OS (with 95% confidence inter-
val) in months from date of first RT to brain.
No ipilimumab Ipilimumab P-value
TTPbr
All patients 3.3 (1.5–6.3) 2.7 (1.5–6.0) 0.55
WBRT 3.3 (1.4–6.3) 2.7 (1.0–8.2) 0.72
SRS 2.6 (not estimable1) 2.6 (1.2 to
not estimable2)
0.95
OS
All patients 5.3 (4.0–7.6) 18.3 (8.1–25.5) 0.002
WBRT 5.3 (4.3–7.6) 3.1 (1.9 to
not estimable2)
0.60
SRS 4.0 (3.2–14.6) 19.9 (15.9 to
not estimable2)
0.009
TTPbr, time to progression in the brain; OS, overall survival; RT, radia-
tion therapy; WBRT, whole brain radiation therapy; SRS, stereotactic
radiosurgery.
1The 95% confidence interval for the median survival time could not
be determined because there were only five patients in this cell.
2The upper limit of the 95% confidence interval for the median
survival time could not be determined because the estimated upper
confidence limit for the survival function for this group never falls
below 0.5 [19].
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Table 4). Partial response to RT was observed in two of
22 patients (9.1%) in the comparison groups, both of
whom were treated with WBRT. Among patients who
were treated with the first dose of ipilimumab prior to
RT, partial responses to RT were observed in four of 10
patients (40.0%), including two who were treated concur-
rently. This is in contrast to two of 12 responses (16.7%)
among patients who received their first dose of
ipilimumab after RT. Notably, one patient started ipi-
limumab soon after completing WBRT (within 3 weeks),
and demonstrated an 80% reduction in her dominant
brain metastasis and complete disappearance of four
smaller ones. The distribution of responses of patients
who received ipilimumab before versus after RT was not
significantly different using Fisher’s exact test (P = 0.224).
No unexpected toxicities from radiation were observed
in these patients. Intratumoral hemorrhage within 30 days
after the start of RT was observed in 4/32 (12.5%)
patients in the comparison groups and 1/25 (3.9%) in the
ipilimumab groups. Three instances of radiation necrosis
were observed, which were all patients in the comparison
groups.
Discussion
The results of this study are consistent with other limited
retrospective data demonstrating that ipilimumab and
SRS are associated with significantly improved survival
[8]. In a previous analysis of 77 patients treated with
SRS, the reported median OS was 21.3 months for
patients treated with SRS and ipilimumab, versus
4.9 months for patients who received SRS alone. In
another retrospective study of ipilimumab and SRS, there
was no statistically significant survival benefit at
6 months, but patients in that analysis did poorly, as
demonstrated by a median OS of 5.9 months and a 30%
rate of intracranial hemorrhage [9]. In the present study,
the survival of the SRS and ipilimumab group was signifi-
cantly longer than that for SRS alone (median of
19.9 months vs. 4.0 months; P = 0.009), with a HR of
0.31 that was statistically significant (P = 0.009). Neither
SRS nor ipilimumab treatment individually appears to
account for the prolonged survival seen in this analysis.
These survival outcomes compare favorably with the
reported survival for patients with MBM who received
monotherapy with either ipilimumab or SRS, which range
from 5 to 7 months [3, 4, 7]. As an adjunct comparison,
we analyzed 20 serial melanoma patients (2011–2012)
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Figure 2. Censored overall survival of patients for each type of
radiation therapy by ipilimumab treatment. (A) WBRT: treatment with
ipilimumab was not associated with survival in the subset of patients
who underwent WBRT (HR = 0.56, P = 0.15); (B) SRS: treatment with
ipilimumab was significantly associated with improved survival in the
subset of patients who underwent SRS (HR = 0.31, P = 0.009).
WBRT, whole brain radiation therapy; HR, hazard ratio; SRS,
stereotactic radiosurgery.
Table 3. Response to RT by type of RT.
WBRT SRS
Complete response 0/27 (0%) 0/17 (0%)
Partial response 5/27 (18.5%) 3/17 (17.6%)
Stable disease 13/27 (48.1%) 7/17 (41.2%)
Progressive disease 9/27 (33.3%) 7/17 (41.2%)
RT, radiation therapy; WBRT, whole brain radiation therapy; SRS,
stereotactic radiosurgery.
Table 4. Response to RT by ipilimumab treatment.
No
ipilimumab
Ipilimumab
before RT
Ipilimumab
after RT
Complete response 0/22 (0%) 0/10 (0%) 0/12 (0%)
Partial response 2/22 (9.1%) 4/10 (40.0%) 2/12 (16.7%)
Stable disease 13/22 (59.1%) 2/10 (20.0%) 5/12 (41.7%)
Progressive disease 7/22 (31.8%) 4/10 (40.0%) 5/12 (41.7%)
RT, radiation therapy.
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without brain metastases who received ipilimumab at the
University of Michigan and found that their median sur-
vival was 15.5 months. These findings strongly support
the combined use of both ipilimumab and radiotherapy
for patients with MBM.
The magnitude of the 16-month survival benefit of both
ipilimumab and SRS treatment over SRS without
ipilimumab suggests that the two treatments may be
synergistic (rather than having independent additive
effects). We found a larger benefit of ipilimumab for those
patients who received SRS, but we did not have adequate
power to determine whether this interaction was statisti-
cally significant. The theory of synergy between ipilimumab
and RT is supported by preclinical and clinical data.
Although the central nervous system previously has been
thought to be an immune sanctuary, it is now known that
activated lymphocytes can cross through the blood–brain
barrier [20]. Preclinical data demonstrate that ionizing
radiation increases the permeability of the blood–brain
barrier [21], induces the presentation of previously occult
cancer antigens to T cells [22], and generates tumor-
specific cytotoxic T lymphocytes [23, 24]. In patients with
MBM, a high level of T-cell immune infiltrate in the
tumors is associated with prolonged survival [25]. In mice,
fractionated RT to a tumor on one flank with concurrent
administration of anti-CTLA-4 antibody induced activated
tumor-specific T cells and inhibited growth of tumors on
the contralateral flank, located outside of the radiation field
[26]. This phenomenon, the regression of tumors at sites
distant to the irradiated site, is known as the abscopal
effect. The abscopal effect was documented in a patient
with metastatic melanoma who was treated with ipi-
limumab for 15 months before she required palliative radi-
ation to a paraspinal mass [27]. She experienced regression
of tumors in the hilar lymph nodes and spleen, accompa-
nied by temporal increases in antibodies to cancer-testis
antigen NY-ESO and activation of CD4+ T cells, suggesting
that the both humoral and cell-mediated immunity play a
role in the abscopal effect. Other cases have been reported,
including a case of a man with brain metastases and nodal
metastases who had a CR to concurrent treatment with
ipilimumab and SRS and developed antibodies to the
tumor antigens MAGEA3 and PASD1 [28].
The dose and schedule of RT may be important factors
in spurring an immune response, but this is not well
understood. In mouse models of breast cancer and colon
cancer, growth inhibition of tumors outside the radiation
field occurred only when anti-CTLA-4 antibody was
given concurrently with fractionated radiation, but not
single-dose radiation [26]. To the contrary, our analysis
suggests that SRS is superior to fractionated WBRT; how-
ever, this may be confounded by the fact that the SRS
patients had fewer brain metastases, and, in general, a
better expected survival. Interestingly, in the mouse study,
RT of three doses of 8 Gy was more effective at synergiz-
ing with the anti-CTLA-4 antibody than five doses of
6 Gy. Our analysis did not include any comparable oligo-
fractionated regimens, as they are not used clinically for
intact brain metastases very often.
Limitations of this study include small sample sizes,
retrospective data collection, and selection bias, meaning
that patients who had more indolent disease may have
been more likely to receive ipilimumab. The comparison
groups and the ipilimumab groups were extremely similar
by all three prognostic indicators (Table 1), but we found
that the subset that received SRS and ipilimumab had
better performance status at baseline and were more likely
to be neurologically asymptomatic, which may have
impacted our findings. While our favorable survival
results could be partially explained by selection bias, we
attempted to include all serial cases of patients in our
census who received ipilimumab, including those with
leptomeningeal involvement and those who were rapidly
progressing. Six patients received only one or two doses
of ipilimumab, generally because they became too ill to
receive the full course of treatment.
Due to the small sample size, we only included
ipilimumab treatment and type of RT in our main Cox
regression model [29]. Patient characteristics were exam-
ined for differences in factors that may have contributed
to the survival outcomes (Table 1). Patients in the
ipilimumab groups received subsequent brain RT signifi-
cantly more frequently. To the best of our knowledge, sal-
vage RT for MBM has not been shown to improve
survival, and thus we did not include subsequent RT in
the multivariate model. There was also significantly more
exposure to BRAF inhibitor therapy in the ipilimumab
groups. BRAF inhibition has a documented survival
advantage in metastatic melanoma without brain metasta-
ses [30]. Dabrafenib appears to be active in MBM, and
median survival was ~8 months in patients with either
untreated or progressive MBM despite local treatment
[31]. Thus, we included BRAF-inhibitor exposure in the
multivariate model, but the effect of ipilimumab over-
shadowed it (HR = 0.50 for ipilimumab treatment vs.
HR = 0.95 for BRAF inhibitor treatment; P = 0.03 and
P = 0.91, respectively). One explanation for the lack of
significance for BRAF inhibitor treatment may be the
strong correlation between treatment with BRAF inhibi-
tors and treatment with ipilimumab. Therefore, even
when considering the higher use of BRAF inhibitors and
subsequent RT, the patients in our analysis had a survival
that is arguably longer than expected.
We did not see evidence of increased toxicity with the
combination treatment. Although intratumoral hemor-
rhage [14] and radiation necrosis [15] have been
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reported, we did not find that there was excess toxicity in
patients who received ipilimumab. In fact, the rate of
intratumoral hemorrhage was higher in the comparison
group. There were five patients who were treated concur-
rently with ipilimumab and RT, one of whom had intra-
tumoral hemorrhage. There was a slight initial decrement
in survival after WBRT that was observed in patients who
received ipilimumab. This does not appear to be explain-
able by increased toxicity but instead may be due to treat-
ment of patients with significantly advanced disease with
lower DS-GPA scores (mean DS-GPA 1.7 vs. 2.2, data not
shown).
It is not clear what the ideal timing of ipilimumab
with respect to RT is, as survival and response outcomes
were conflicting in subgroup analyses of treatment
sequences. Response rates were higher in the ipilimumab
group, especially when ipilimumab was given prior to RT
(40% vs. 17% in the ipilimumab after RT group and 9%
in the comparison groups that did not receive ipi-
limumab). Among the six responding patients in the ipi-
limumab group, four of them were treated with
ipilimumab prior to RT (including two treated concur-
rently), and the fifth received ipilimumab shortly after
completing WBRT. In a subgroup analysis, survival
seemed to be improved for the patients who received ipi-
limumab after RT as compared to patients who received
ipilimumab prior to RT (median of 18.4 months vs.
8.1 months). OS is affected by multiple factors, and
favorable selection bias likely applies more to the groups
that received ipilimumab after RT, as some of the
patients received RT in 2009–2010 and they lived long
enough to reach the FDA approval of ipilimumab in
2011. The survival data and response data for sequence
of ipilimumab and RT are somewhat conflicting, but the
response data are likely more informative in this regard.
Sequence will be important to explore in future clinical
trial designs. Previous studies support the approach of
immunotherapy prior to RT. In the preipilimumab era,
immunotherapy prior to SRS was associated with statisti-
cally significant gains in survival in other retrospective
studies [4, 32], but not all [3]. In 333 patients who
underwent SRS for MBM, the history of prior immuno-
therapy (interleukin-2 or interferon), but not subsequent
immunotherapy, was associated with improved survival
of 13.8 months, as compared to 5.8 months in the group
that did not receive prior immunotherapy [4]. Assuming
that OS in the ipilimumab after RT group is more sus-
ceptible to selection bias, and taking into account the
available positive data on immunotherapy prior to SRS,
our data lend weight to the idea that pretreatment with
ipilimumab before RT (and perhaps given shortly after
RT) may improve the rate of response to RT; the impact
on survival is unclear but deserves further study.
Conclusions
In our analysis, ipilimumab therapy was associated with
improved OS in patients with MBM who received RT, and
the median survival of patients in the ipilimumab and SRS
group was nearly five times the group who received SRS
alone. This is the second single-institution retrospective
study to report a 16-month survival benefit for this popula-
tion [8]. The magnitude of the benefit suggests that the effect
of ipilimumab could be synergistic with focused high-dose
RT. The optimal sequence of combination therapy with
ipilimumab and RT is not known, but a multimodality
approach appears to be essential to optimize patient out-
comes. Prospective studies are on-going.
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